Shield Therapeutics offers a high-risk, high-upside turnaround built on ACCRUFeR’s clinical differentiation, Viatris-powered U.S. scale, and a fragile but improving path to profitability.
Overview
Shield Therapeutics is a commercial-stage specialty pharma company whose value is concentrated in ferric maltol, sold as ACCRUFeR in the U.S. and FeRACCRU internationally. The product addresses iron deficiency with a better-tolerated oral alternative to generic ferrous salts and a cheaper, more convenient option than IV iron. U.S. commercialization is shared with Viatris, while international markets use licensing partnerships. FY25 revenue reached $49.7 million, led by $45.8 million of U.S. net product sales and about 199,000 ACCRUFeR prescriptions.